<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90647">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01813253</url>
  </required_header>
  <id_info>
    <org_study_id>DE766-A-J302</org_study_id>
    <nct_id>NCT01813253</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer</brief_title>
  <official_title>A Randomized, Open-label, Japan-Korea Collaborative Phase 3 Study to Compare the Efficacy of Nimotuzumab and Irinotecan Combination Therapy Versus Irinotecan Monotherapy as Second Line Treatment in Subjects With Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuhnil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kuhnil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate overall survival of nimotuzumab in combination with irinotecan
      compared to irinotecan alone in subjects with EGFR overexpressed advanced gastric or
      gastroesophageal junction cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, open-label, Japan and Korea collaborative, phase 3 study will evaluate
      overall survival of nimotuzumab in combination with irinotecan compared to irinotecan alone
      in subjects with EGFR overexpressed advanced gastric or gastroesophageal junction cancer.
      Approximately 400 subjects will be randomized in a 1:1 ratio to receive irinotecan (control
      group) or nimotuzumab and irinotecan (combination group). Nimotuzumab and/or irinotecan
      should be continued until disease progression or intolerable toxicity. Nimotuzumab is
      administered at 400 mg once weekly as an intravenous infusion and irinotecan is administered
      at 150 mg/m2 once every 2 weeks as an intravenous infusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Around 4.5 years  after first subject randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival is defined as the time from the date of randomization to the date of the death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Around 4.5 years after first subject randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression Free Survival is defined as the time from the date of randomization to the date of progression or death from any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Around 4.5 years after first subject randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Response Rate is defined as the proportion of subjects with CR or PR in the best overall response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Around 4.5 years after first subject randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease Control Rate is defined as the proportion of subjects with CR, PR or SD in the best overall response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Around 4.5 years after first subject randomization</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of adverse events using latest CTCAE version 4 including minor version</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan and nimotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adminitration of irinotecan 150 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of irinotecan 150 mg/m2 IV once every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops</description>
    <arm_group_label>Irinotecan and nimotuzumab</arm_group_label>
    <arm_group_label>Irinotecan</arm_group_label>
    <other_name>Boryung irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>400mg IV once weekly until progression or unacceptable toxicity develops</description>
    <arm_group_label>Irinotecan and nimotuzumab</arm_group_label>
    <other_name>DE-766</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced or recurrent subjects with gastric or gastroesophageal junction
             adenocarcinoma.

          2. Subjects who experienced disease progression during first line or within 6 months
             after the last dose of first line therapy.  The first line regimen must have
             contained a 5-fluorouracil based agent and platinum agent.

          3. Subjects with EGFR overexpression (2+ or 3+ in IHC)

        Exclusion Criteria:

          1. Subjects who have received irinotecan

          2. Subjects who have received EGFR-directed therapy

          3. Other active malignancy within the last 5 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mee young Hwang</last_name>
    <phone>82-2-2175-9763</phone>
    <email>myhwang@kuhnil.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyung sun Shin</last_name>
    <phone>82-2-2175-9758</phone>
    <email>ksshin@kuhnil.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-0882</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nozomu Fuse</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hwansun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 12, 2013</lastchanged_date>
  <firstreceived_date>March 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epidermal growth factor receptor</keyword>
  <keyword>second line</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
